This phase II multicenter study evaluated the efficacy and tolerability of vandetanib monotherapy compared to vandetanib plus gemcitabine or gemcitabine plus placebo in patients with advanced biliary tract cancer (BTC). Vandetanib treatment did not improve progression-free survival (PFS) in patients with advanced BTC.

READ FULL ARTICLE Curated publisher From Mdlinx